Keith Orford

Dr. Keith Orford oversees the translational medicine and clinical development initiatives for FogPharma as Chief Medical Officer and Executive Vice President of Clinical and Translational Science.

Prior to joining Fog, Dr. Orford was the Chief Medical Officer of Calithera Biosciences, where he led the Clinical group, including Clinical Development, Clinical Operations, Biometrics, Pharmacovigilance, and Medical Affairs. Prior to Calithera, Dr. Orford was the Clinical Development Lead in the Immuno-Oncology and Combinations Development Performance Unit at GlaxoSmithKline, where he oversaw clinical development, including multiple early-stage clinical trials with targeted agents and immunotherapies. Bef GlaxoSmithKline, Dr. Orford was at Merck, where he worked on early clinical development programs across therapeutic areas. Previously, Dr. Orford was a Research Fellow and Instructor at Massachusetts General Hospital and Harvard Medical School, where he trained in Internal Medicine and completed a postdoctoral fellowship in the laboratory of Dr. David Scadden, studying epigenetic regulation of hematopoietic and embryonic stem cell differentiation.

Dr. Orford received his undergraduate, M.D., and Ph.D. degrees from Georgetown University. His Ph.D. research elucidated the mechanism by which b-catenin is regulated by the Wnt signaling pathway.